SCHEMBL19783204

SCHEMBL19783204

COc1ccc(C)c2nc(Br)sc12

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.49
NQO2 P16083 3/20 0.44
HPGD P15428 3/20 0.41
TSHR P16473 3/20 0.41
HSD17B10 Q99714 3/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
LMNA P02545 1/20 0.41
TP53 P04637 1/20 0.41
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
POLB P06746 1/20 0.40
CHRM4 P08173 3/20 0.40
MAPT P10636 3/20 0.40
DUSP3 P51452 1/20 0.39
KDM4E B2RXH2 3/20 0.39
GAA P10253 1/20 0.38
CYP3A4 P08684 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
MAPK1 P28482 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30189716 1.00 ALDH1A1 (0.49) ALDH1A1NQO2HPGDTSHRHSD17B10
SCHEMBL7405867 0.87 ALDH1A1 (0.57) ALDH1A1NQO2HPGDTSHRHSD17B10
SCHEMBL14970046 0.83 HSD17B10 (0.54) ALDH1A1NQO2HPGDTSHRHSD17B10
SCHEMBL19782849 0.80 ALDH1A1 (0.77) ALDH1A1HPGDTSHRHSD17B10SMN1; SMN2
SCHEMBL18416893 0.80 CYP3A4 (0.56) ALDH1A1HPGDTSHRHSD17B10SMN1; SMN2
SCHEMBL30189600 0.80 ALDH1A1 (0.77) ALDH1A1HPGDTSHRHSD17B10SMN1; SMN2
SCHEMBL30189863 0.80 CYP3A4 (0.56) ALDH1A1HPGDTSHRHSD17B10SMN1; SMN2
SCHEMBL6171797 0.78 ALDH1A1 (0.53) ALDH1A1NQO2HPGDTSHRHSD17B10
SCHEMBL10220132 0.77 ALDH1A1 (0.45) ALDH1A1HPGDTSHRHSD17B10SMN1; SMN2
SCHEMBL10271391 0.77 ALDH1A1 (0.45) ALDH1A1HPGDTSHRHSD17B10SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210163465-A1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2021-06-03 US disclosed
US-20190292176-A1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS BISTOL MYERS SQUIBB COMPANY (US) 2019-09-26 US disclosed
WO-2018013774-A1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS BRISTOL-MYERS SQUIBB COMPANY (US) 2018-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190292176-A1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS F2, F2RL3, PF4 ALDH1A1 1618/4885NQO2 756/4885HPGD 866/4885
US-20210163465-A1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS F2, F2RL3, F12 ALDH1A1 1598/4885NQO2 851/4885HPGD 1104/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.